Universal Detection Technology Addresses Bioterrorism Threat to National Security at ASIS 2009

As U.S. Senate Bill Addressing Risk of Biological Attack Undergoes Revue, Company Showcases Latest in First Responder Technology with Five Agent Biodetection Kit – ASIS International’s 55th Annual Seminar and Exhibits

LOS ANGELES–Universal Detection Technology (www.udetection.com)(OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it will be showcasing its TS-10-5-agent biodetection kit at ASIS International 2009 in Anaheim, California.

Universal Detection Technology’s kits, recently certified by DHS as an “Approved Product for Homeland Security” under the Support Anti-terrorism by Fostering Effective Technologies (SAFETY) Act of 2002, are the industry’s only hand-held assay designed to detect and identify up to five separate threats using one sample in a single, easy-to-use device. The kits equip first responders with an effective tool for the rapid onsite detection of up to five biological warfare agents: anthrax, ricin, botulinum toxin, Y. pestis (plague) and Staphylococcal Enterotoxin B (SEB). Detection time is under three minutes.

“With the Senate bill introduced earlier this month that calls for strengthening security against the risk of a biological attack, Universal Detection Technology is prepared to meet the growing needs of domestic and international bioterrorism prevention and response,” said Jacques Tizabi, CEO of Universal Detection Technology. “Through this international gathering of security professionals, ASIS International 2009 is a perfect forum for demonstrating the easy implantation and cost effectiveness of these much-needed bioterrorism monitoring tools for first responders,” said Tizabi.

Universal Detection Technology will showcase its TS-10-5-agent biodetection kit with live and taped demonstrations at booth #375 at the event, held on September 21-24, 2009 at the Anaheim Convention Center in Anaheim, California. Members of UDT’s executive team, including R&D and business development, will be present to answer questions about the product and the company. After participating in the demonstration, visitors will also have a chance to win a biodetection kit for their agency or company.

Universal Detection Technology’s biodetection kits have been used extensively by first responders, government agencies and private industry throughout the country. Recently, UDT received a contract from the U.S. Army to use the kits at an intelligence site. The company also signed a distribution pact with Strategic Response Initiatives. The equipment’s capacities feature the following:

* No cross-reactivity with near neighbor strains

* No cross-reactivity to household powders

* No set up time

* No expensive reader needed

* No decontamination requirements

* No false positives

* No false negatives

* No hook effect

For more information, please visit www.udetection.com or email info@udetection.com.

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, Universal Detection Technology, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems and antimicrobial products. www.udetection.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that involve known and unknown risks and uncertainties, which may cause the Company’s actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.